698 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Bought by Kestra Investment Management LLC

Kestra Investment Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 698 shares of the company’s stock, valued at approximately $233,000.

Other hedge funds also recently made changes to their positions in the company. Tidal Investments LLC boosted its holdings in shares of Medpace by 16.2% in the first quarter. Tidal Investments LLC now owns 874 shares of the company’s stock valued at $353,000 after acquiring an additional 122 shares during the period. Cetera Investment Advisers grew its position in Medpace by 235.0% during the 1st quarter. Cetera Investment Advisers now owns 11,494 shares of the company’s stock worth $4,645,000 after purchasing an additional 8,063 shares during the last quarter. Cetera Advisors LLC increased its stake in Medpace by 162.4% in the first quarter. Cetera Advisors LLC now owns 2,608 shares of the company’s stock valued at $1,054,000 after purchasing an additional 1,614 shares during the period. GAMMA Investing LLC raised its holdings in shares of Medpace by 58.4% in the second quarter. GAMMA Investing LLC now owns 236 shares of the company’s stock valued at $97,000 after buying an additional 87 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Medpace by 38.8% during the second quarter. CWM LLC now owns 2,323 shares of the company’s stock worth $957,000 after buying an additional 649 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on MEDP. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird boosted their target price on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday, November 25th. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $420.00 to $350.00 in a report on Friday, September 27th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Finally, Redburn Atlantic initiated coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $380.56.

Medpace Stock Performance

Medpace stock opened at $342.36 on Tuesday. Medpace Holdings, Inc. has a one year low of $273.14 and a one year high of $459.77. The company has a market cap of $10.64 billion, a P/E ratio of 29.98, a price-to-earnings-growth ratio of 1.88 and a beta of 1.37. The business has a fifty day moving average of $337.43 and a two-hundred day moving average of $370.62.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter last year, the business earned $2.22 earnings per share. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.